Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II randomized open-label study of RO7247669 + axitinib with or without tiragolumab versus pembrolizumab + axitinib in previously untreated advanced or metastatic renal cell carcinoma
2021-006430-39Phase 2Active
- Sponsor
- Roche
- Start
- Dec 2022
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes, Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of tobemstomig, tiragolumab, axitinib and pembrolizumab in renal cell carcinoma (RCC) (3 arms), sponsored by Roche. Primary endpoint: Progression-free survival. Started Dec 2022; status: active.
02
Drugs
03
Conditions
renal cell carcinoma (RCC)
Beyond the preview
Go deeper on 2021-006430-39.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2021-006430-39.